How Much Does Trulicity Cost in Montana in 2026?

Montana Retail Price for Trulicity in 2026

The average cash-pay price for Trulicity across Montana retail pharmacies sits at $931 per month in 2026, matching the Eli Lilly list price. That figure covers a box of four prefilled single-dose pens, each delivering one weekly injection. Pricing does not vary meaningfully between Billings, Missoula, Great Falls, or smaller Montana communities because wholesale acquisition cost remains standardized across pharmacy chains [1].

Dulaglutide earned FDA approval in 2014 as a once-weekly GLP-1 receptor agonist for type 2 diabetes [2]. Eli Lilly later gained a cardiovascular indication based on the REWIND trial (N=9,901), which demonstrated a 12% reduction in major adverse cardiovascular events (MACE) over a median 5.4-year follow-up with dulaglutide 1.5 mg versus placebo [3]. The drug is available in 0.75 mg, 1.5 mg, 3.0 mg, and 4.5 mg doses, and the American Diabetes Association Standards of Care recommend GLP-1 receptor agonists as preferred second-line agents for patients with type 2 diabetes who have established atherosclerotic cardiovascular disease or high cardiovascular risk [4].

Montana patients without insurance should compare prices at independent pharmacies, Costco, and mail-order services. GoodRx and RxSaver discount cards can reduce the cash price to approximately $830 to $880 at some Montana locations, though savings vary by pharmacy.

Montana Medicaid Does Not Cover Trulicity

Montana Medicaid, administered through the Montana Department of Public Health and Human Services, does not include Trulicity on its preferred drug list for 2026. Patients enrolled in Montana Medicaid who need a GLP-1 receptor agonist for type 2 diabetes are typically directed toward formulary alternatives.

The ADA Standards of Care list several GLP-1 receptor agonists with cardiovascular or renal benefit, including semaglutide (Ozempic) and liraglutide (Victoza) [5]. Medicaid formularies across states vary considerably in which GLP-1 agents they cover. A 2023 analysis published in Diabetes Care found that Medicaid prior-authorization requirements for GLP-1 receptor agonists delayed treatment initiation by a median of 21 days and reduced fill rates by 32% compared to plans without such barriers [6].

Providers can file a prior-authorization exception with Montana Medicaid if a patient has a documented clinical need for dulaglutide specifically (for example, failure on or intolerance to a preferred GLP-1 agent). Approval is not guaranteed, and the process typically takes 7 to 14 business days. Patients denied Medicaid coverage may appeal through the Montana Fair Hearings process.

Commercial Insurance Coverage in Montana

Most large commercial insurers operating in Montana, including Blue Cross Blue Shield of Montana, Pacific Source, and Allegiance, cover Trulicity on a non-preferred or specialty tier with prior authorization. Copays for commercially insured patients range from $25 to $150 per month depending on plan design and tier placement.

Prior authorization criteria generally require documentation of: a confirmed diagnosis of type 2 diabetes, an A1C at or above 7.0% despite metformin therapy (or metformin intolerance), and no contraindications to GLP-1 agonists [7]. The Endocrine Society Clinical Practice Guideline for type 2 diabetes pharmacotherapy recommends GLP-1 receptor agonists for patients with A1C above target on metformin, particularly those with cardiovascular or renal comorbidities [8].

Step therapy is common. Many Montana plans require that patients try metformin (and sometimes a sulfonylurea or SGLT2 inhibitor) before approving a GLP-1 agonist. A study in the Journal of Managed Care & Specialty Pharmacy reported that step-therapy protocols for GLP-1 receptor agonists increased time-to-treatment by an average of 45 days and were associated with 17% lower persistence at 12 months [9].

Montana state employees on the State Group Benefits Plan should check whether Trulicity falls on a specialty or preferred brand tier, as tier placement changed for several GLP-1 agents in the 2026 plan year.

The Eli Lilly Trulicity Savings Card

Eli Lilly offers the Trulicity Savings Card, which reduces out-of-pocket cost to as low as $25 per month for eligible commercially insured patients. The card covers up to $150 in out-of-pocket costs per 30-day fill and can be used for up to 24 months.

Eligibility requirements: the patient must have commercial insurance that covers Trulicity, must not be enrolled in any government-funded healthcare program (Medicare, Medicaid, Tricare, VA), and must be a U.S. resident age 18 or older. The card is accepted at all major Montana pharmacies, including Walgreens, Albertsons, and independent pharmacies.

Patients should be aware that savings-card spending does not count toward insurance deductibles or out-of-pocket maximums. A 2022 JAMA Internal Medicine study found that manufacturer copay cards for branded diabetes drugs delayed generic substitution and increased total healthcare spending by an estimated $2.7 billion annually across the U.S. [10]. For Montana patients, the practical benefit remains significant: $25 per month versus $931 per month is a 97% cost reduction.

Eli Lilly also operates the Lilly Cares Foundation Patient Assistance Program for uninsured patients who meet income eligibility requirements (household income at or below 400% of the federal poverty level). Approved patients receive Trulicity at no cost.

Compounded Dulaglutide in Montana

Compounded dulaglutide is available in Montana through licensed 503A compounding pharmacies. This is legal. Section 503A of the Federal Food, Drug, and Cosmetic Act permits patient-specific compounding by state-licensed pharmacies operating under a valid prescription [11].

Montana's Board of Pharmacy regulates compounding under Montana Code Annotated Title 37, Chapter 7. A compounding pharmacy in Montana must hold a valid state license, compound pursuant to an individual patient prescription, and comply with USP <797> sterile compounding standards [12]. The pharmacy cannot compound copies of commercially available drugs unless the prescriber documents a clinical difference (for example, a dose or formulation not available commercially).

The cost of compounded dulaglutide varies by pharmacy but typically runs $200 to $450 per month, representing a 50% to 75% reduction compared to brand Trulicity. Patients should confirm that their compounding pharmacy is licensed by the Montana Board of Pharmacy and accredited by the Pharmacy Compounding Accreditation Board (PCAB) for added quality assurance. The FDA's 2023 guidance on compounding clarified that dulaglutide, as a biologic, falls under specific regulatory considerations for compounding [13].

A key distinction: brand Trulicity undergoes rigorous FDA batch testing with established bioequivalence data. Compounded versions are not FDA-approved products and do not undergo the same regulatory review. The Endocrine Society and ADA have emphasized that compounded peptides should only be used when brand product is unavailable or unaffordable, and only from appropriately licensed pharmacies [14][15].

Telehealth Prescribing of Trulicity in Montana

Montana permits telehealth prescribing of Trulicity. The Montana Board of Medical Examiners authorizes licensed physicians, nurse practitioners, and physician assistants to prescribe controlled and non-controlled medications via telehealth, including GLP-1 receptor agonists, after establishing a valid patient-provider relationship through a synchronous audio-video visit.

Multiple telehealth platforms now serve Montana patients for GLP-1 prescribing. A 2024 study in Diabetes, Obesity and Metabolism found that telehealth-managed GLP-1 agonist therapy produced A1C reductions comparable to in-person care (mean A1C reduction of 1.2% vs. 1.3%) over 12 months, with higher medication adherence rates in the telehealth group (78% vs. 71%) [16].

For Montana residents in rural counties, telehealth access is especially relevant. Thirty-four of Montana's 56 counties qualify as frontier (fewer than six people per square mile), and many lack endocrinology or diabetology specialists. The CDC's National Diabetes Statistics Report estimates that 10.1% of Montana adults have diabetes, with type 2 diabetes accounting for 90% to 95% of cases [17].

Telehealth providers can prescribe Trulicity and either ship it directly or send the prescription to a local Montana pharmacy. Patients using telehealth should confirm their provider can complete the prior-authorization paperwork required by their insurance plan.

Saving Money on Trulicity in Montana: A Cost Comparison

Montana patients have several paths to reduce Trulicity costs. Here is a direct comparison of the primary options:

Brand Trulicity at retail price. $931 per month. No insurance. Full cash pay at any Montana pharmacy.

Brand Trulicity with commercial insurance. $25 to $150 per month. Requires prior authorization. Most Montana commercial plans cover Trulicity on a non-preferred tier.

Brand Trulicity with Eli Lilly Savings Card. As low as $25 per month. Requires commercial insurance. Not valid with government insurance.

Eli Lilly Patient Assistance Program. $0 per month. For uninsured patients at or below 400% of the federal poverty level.

Compounded dulaglutide (503A pharmacy). Approximately $200 to $450 per month. Requires a prescription. Must use a Montana-licensed compounding pharmacy.

GoodRx or discount card. $830 to $880 per month. Modest savings on cash price. No insurance required.

A Health Affairs analysis found that out-of-pocket costs above $50 per month for diabetes medications reduced adherence by 24% over 12 months [18]. For Montana patients facing the full $931 monthly price, exploring every available savings mechanism is not optional. It directly affects glycemic outcomes.

Clinical Efficacy: What Trulicity Does at Each Dose

Dulaglutide's clinical data supports dose-dependent A1C reduction and weight loss. Understanding what to expect at each dose helps Montana patients and providers plan treatment.

The AWARD-11 trial (N=1,842) compared dulaglutide 3.0 mg and 4.5 mg to 1.5 mg in patients with type 2 diabetes on metformin [19]. At 36 weeks, A1C reductions from a baseline of approximately 8.6% were: 1.5 mg reduced A1C by 1.53%, 3.0 mg by 1.71%, and 4.5 mg by 1.87%. Body weight decreased by 3.0 kg, 4.0 kg, and 4.7 kg respectively.

The REWIND trial established cardiovascular benefit at the 1.5 mg dose, with a hazard ratio for MACE of 0.88 (95% CI: 0.79 to 0.99) over median 5.4-year follow-up [3]. The study enrolled patients at a mean age of 66 years, with 31% having prior cardiovascular events and 69% having cardiovascular risk factors only. This broad enrollment pattern means the cardiovascular benefit applies to a wide range of Montana patients with type 2 diabetes.

Gastrointestinal side effects are the most common reason for discontinuation. In AWARD-11, nausea occurred in 12% to 16% of patients across doses, vomiting in 5% to 9%, and diarrhea in 8% to 10% [19]. The FDA prescribing information notes that these effects are typically transient and decrease over the first 4 to 8 weeks of therapy [2].

How Trulicity Compares to Other GLP-1 Agonists Available in Montana

Montana patients and providers weighing Trulicity against alternatives should consider efficacy, cost, and formulary status.

Semaglutide (Ozempic) produced greater A1C reduction (1.8% vs. 1.4%) and weight loss (6.5 kg vs. 3.0 kg) compared to dulaglutide 1.5 mg in the SUSTAIN-7 trial (N=1,201) at 40 weeks [20]. Ozempic carries a list price of approximately $935 per month, nearly identical to Trulicity. Montana Medicaid formulary placement differs between agents, so patients should verify which GLP-1 agonist their plan prefers.

Liraglutide (Victoza) requires daily injection versus the weekly dosing of Trulicity. The LEADER trial (N=9,340) showed a 13% MACE reduction with liraglutide, comparable to REWIND's 12% reduction with dulaglutide, though the trials differed in population characteristics and follow-up duration [21]. Victoza's list price is approximately $1,050 per month.

Tirzepatide (Mounjaro), a dual GIP/GLP-1 receptor agonist, produced A1C reductions of 2.0% to 2.4% in the SURPASS trials and is gaining Montana formulary coverage [22]. It is priced comparably to Trulicity. For patients with type 2 diabetes who need greater glycemic or weight-loss efficacy, tirzepatide may be a cost-neutral switch if the insurance plan covers both agents at the same tier.

Steps to Get Trulicity at the Lowest Cost in Montana

Montana patients should follow a specific sequence to minimize what they pay.

First, confirm your insurance formulary status. Call the member services number on the back of your insurance card and ask whether Trulicity is covered and on which tier. Ask about prior-authorization requirements and step-therapy rules.

Second, if commercially insured, enroll in the Eli Lilly Trulicity Savings Card before filling the prescription. The card can be activated online or through your prescriber's office.

Third, if uninsured, apply to the Lilly Cares Patient Assistance Program. The application requires proof of income and a prescriber signature. Processing takes 4 to 6 weeks.

Fourth, if the above options do not bring costs below $200 per month, ask your prescriber about compounded dulaglutide from a Montana-licensed 503A pharmacy. The prescriber must write a patient-specific prescription and may need to document a clinical justification.

Fifth, for Montana Medicaid patients, request a formulary exception. Your prescriber should submit documentation of prior treatment failures or clinical rationale for dulaglutide specifically. The Medicaid pharmacy benefit helpline can guide the exception-request process.

According to the National Institute of Diabetes and Digestive and Kidney Diseases, achieving and maintaining glycemic targets reduces the risk of microvascular complications by 25% to 40% over 10 years [23]. The financial barrier to GLP-1 therapy in Montana is real, but multiple pathways exist to reduce or eliminate it.